Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
06 May 2016Website:
http://www.intelliatx.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | 37 min agoDividend
Analysts recommendations
Institutional Ownership
NTLA Latest News
Seemingly encouraging results from the lab were met with some notable skepticism.
Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Call to Discuss NTLA-2002 Phase 2 Study Results Call October 24, 2024 11:00 AM ET Company Participants Lina Li - Senior Director, Investor Relations and Corporate Communications John Leonard - Chief Executive Officer David Lebwohl - Chief Medical Officer. Danny Cohn - Internist, Department of Vascular Medicine, Amsterdam University Medical Center Paula Busse - Professor of Medicine, Division of Clinical Immunology Jim Butler - General Manager, NTLA-2002 Program, Conference Call Participants Luca Issi - RBC Maury Raycroft - Jefferies Mani Foroohar - Leerink Partners Chris Yu - Morgan Stanley Gena Wang - Barclays Dae Gon Ha - Stifel Kostas Biliouris - BMO Capital Markets Rick Bienkowski - Cantor Fitzgerald William Pickering - Bernstein Ray Forset - Guggenheim Timur Ivannikovon - Raymond James Jay Olson - Oppenheimer Operator Good morning, and welcome to the Intellia Therapeutics Investor Event.
Intellia Therapeutics' innovative gene editing technology could revolutionize medicine, but investors need a strong stomach for volatility.
- Investor webcast to review the NTLA-2002 Phase 2 data is now planned for Thursday, October 24 at 8:30 a.m. ET
These stocks haven't performed well this year.
Intellia starts the pivotal phase III HAELO study on NTLA-2002 for the treatment of hereditary angioedema (HAE).
CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that interim data from the ongoing Phase 1 study of nexiguran ziclumeran (nex-z, also known as NTLA-2001) will be presented in a late-breaking oral presentation at the 2024 American Heart Association (AHA) Scientific Sessions, taking place November 16 – 18 in Chicago, Illinois. Nex-z is an investigational in vivo CRISPR-based gene editing therapy designed to be a single-dose treatment for transthyretin (ATTR) amyloidosis. Intellia leads development and commercialization of nex-z as part of a multi-target discovery, development and commercialization collaboration with Regeneron. The presentation will include safety, reduction in serum TTR and biomarkers of disease progression, and functional capacity data in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM).
Cathie Wood invests in businesses that are risky, but with a lot of upside. Intellia Therapeutics has a couple of key readouts coming up.
Intellia Therapeutics is pioneering in-vivo CRISPR gene editing, aiming for groundbreaking therapies, with NTLA-2001 showing promising results in ATTR amyloidosis, potentially achieving blockbuster status. Despite a 65% stock drop since 2022, Intellia's advancements in Phase 3 trials and strong partnerships, like with Regeneron, make it a compelling buy opportunity. The company's innovative use of lipid nanoparticles for gene delivery and a robust pipeline position it as a leader in the CRISPR space, targeting large markets.
Intellia's (NTLA) second-quarter 2024 earnings and revenues lag estimates. The company provides developmental and regulatory updates on its pipeline candidates.
What type of business is Intellia Therapeutics?
Intellia Therapeutics, Inc. is a biotechnology company that focuses on developing therapeutic treatments based on genome editing (CRISPR/Cas9 technology). The company was founded in 2014. Its headquarters, offices, and laboratories are located in Cambridge, Massachusetts. The technology being developed by Intellia has the potential to transform modern medicine by allowing the editing of disease-related genes in one treatment, creating new engineered cell therapy methods that can replace a patient's sick cells or effectively target various types of cancer and autoimmune diseases. The company is harnessing its full potential to develop a potentially new class of therapeutic products for patients with severe and life-threatening illnesses.
What sector is Intellia Therapeutics in?
Intellia Therapeutics is in the Healthcare sector
What industry is Intellia Therapeutics in?
Intellia Therapeutics is in the Biotechnology industry
What country is Intellia Therapeutics from?
Intellia Therapeutics is headquartered in United States
When did Intellia Therapeutics go public?
Intellia Therapeutics initial public offering (IPO) was on 06 May 2016
What is Intellia Therapeutics website?
https://www.intelliatx.com
Is Intellia Therapeutics in the S&P 500?
No, Intellia Therapeutics is not included in the S&P 500 index
Is Intellia Therapeutics in the NASDAQ 100?
No, Intellia Therapeutics is not included in the NASDAQ 100 index
Is Intellia Therapeutics in the Dow Jones?
No, Intellia Therapeutics is not included in the Dow Jones index
When was Intellia Therapeutics the previous earnings report?
No data
When does Intellia Therapeutics earnings report?
The next expected earnings date for Intellia Therapeutics is 08 November 2024